Respiratory Allergy Panel: Inhalant Allergens, Specific IgE, Asthma, and Rhinitis

A respiratory allergy panel measures specific IgE antibodies to selected airborne allergens, such as pollens, dust mites, animal dander, molds, and cockroach. The test can help connect seasonal or year-round nose, eye, and airway symptoms with likely triggers, especially when skin testing is not practical. A positive result shows sensitization—an immune system has made IgE that recognizes the tested allergen. It does not prove that exposure causes symptoms, and the number does not measure asthma severity. A negative panel also does not exclude every respiratory allergy because panels contain a limited, region-dependent list and some people have local allergic responses that are not detected in blood. The most useful interpretation combines the results with symptom timing, geography, home and work exposures, medication use, lung testing, and the pollen or mold calendar. Testing should lead to a specific action, such as targeted exposure reduction, better rhinitis or asthma treatment, focused skin testing, or consideration of allergen immunotherapy.

• A positive inhalant-specific IgE result means sensitization, not automatically clinical allergy.
• Common panels include dust mites, cat, dog, grasses, trees, weeds, molds, and cockroach, but the exact list varies.
• The value should match symptoms and exposure timing before an allergen is called a trigger.
• Specific IgE can support allergic asthma, but spirometry or other objective lung testing is needed to diagnose asthma.
• Antihistamines do not usually need to be stopped for a blood panel, unlike skin-prick testing.
• A broad positive profile may reflect cross-reactivity, high total IgE, or true multiple allergies and may need focused follow-up.

Table of Contents

• What a Respiratory Panel Tests
• Choosing the Right Allergens
• Reading Specific IgE Results
• Rhinitis, Conjunctivitis, and Sinus Symptoms
• Asthma and Lower-Airway Symptoms
• False Positives, Cross-Reactivity, and Gaps
• Turning Results Into a Treatment Plan

What a Respiratory Panel Tests

A respiratory panel is a group of blood tests for allergen-specific immunoglobulin E, or specific IgE. Each test asks whether the person has IgE antibodies that bind to one allergen extract. The laboratory may run the tests separately or report them under a regional “inhalant,” “environmental,” or “respiratory” profile.

Common categories include:

• House dust mites: often Dermatophagoides pteronyssinus and D. farinae;
• Animals: cat dander, dog dander, and sometimes horse, mouse, rat, or other occupational animals;
• Tree pollens: such as birch, alder, oak, maple, cedar, olive, or local species;
• Grass pollens: timothy, Bermuda, Johnson, orchard, ryegrass, or a grass mix;
• Weed pollens: ragweed, mugwort, sagebrush, Russian thistle, or plantain;
• Molds: Alternaria, Cladosporium, Aspergillus, and Penicillium;
• Cockroach: commonly German cockroach;
• Other regional allergens: mouse urine proteins, storage mites, or occupational substances.

The test uses serum, the liquid portion of clotted blood. Allergen proteins are fixed to a solid surface, the serum is added, and bound IgE is measured. Results are usually reported in kilounits of allergen-specific IgE per liter, written kUA/L. Some laboratories also assign a class from 0 to 6. The numerical value is more informative than the class because class boundaries differ and compress a wide range of values.

A typical analytical detection point is around 0.10 kUA/L, while some reports use 0.35 kUA/L as a conventional positive threshold. Neither cutoff separates symptomatic allergy perfectly from harmless sensitization. Low detectable values may matter in a person with a strong exposure-related history, while a much higher value may be irrelevant in someone who encounters the allergen without symptoms.

The panel does not measure airborne allergen concentration, airway inflammation, lung function, total IgE, or the likelihood of an asthma attack. It also does not test irritants such as perfume, smoke, cleaning fumes, cold air, or pollution. These exposures can trigger rhinitis or asthma without an IgE mechanism.

A respiratory panel differs from a food panel. Cross-reactive pollen proteins can produce low positive food-specific IgE, but inhalant testing cannot diagnose food allergy. It also differs from patch testing, which evaluates delayed contact dermatitis rather than immediate IgE sensitization.

Choosing the Right Allergens

The best panel is not the largest one. It is the set that reflects the person’s location, seasons, buildings, animals, hobbies, and work. Testing dozens of unlikely allergens increases the chance of results that do not explain symptoms.

Start with the exposure story. Useful details include:

• whether symptoms are seasonal, year-round, or episodic;
• months when symptoms begin and end;
• improvement during travel or time away from home;
• bedroom humidity, carpeting, visible dampness, and pests;
• contact with cats, dogs, horses, rodents, birds, or farm animals;
• gardening, mowing, composting, grain handling, woodworking, or laboratory work;
• symptom changes at work, school, or a specific building;
• thunderstorms, outdoor exercise, and wildfire or pollution exposure.

Regional pollen calendars matter. Birch may be a major spring allergen in northern climates, olive in Mediterranean areas, and mountain cedar in parts of the southern United States. Ragweed seasons vary with latitude and weather. A generic national panel can miss locally important species while including plants that do not grow nearby.

Year-round symptoms often prompt testing for dust mites, animals, cockroach, and indoor molds. Seasonal symptoms suggest tree, grass, or weed pollens. This division is not absolute. Indoor animal allergen can travel on clothing into schools and offices, and pollen can enter homes. Molds may fluctuate with outdoor weather or indoor moisture.

Occupational asthma or rhinitis needs a tailored approach. Bakers may react to wheat flour enzymes, laboratory workers to rodents, health-care workers to latex or disinfectants, and animal handlers to species-specific proteins. Standard respiratory panels may omit the relevant occupational allergen. Comparing symptoms on workdays and days away, plus specialist-directed testing, is often more useful than adding another general panel.

Children do not need a different biological test, but the allergen list and interpretation should fit age and exposure. Sensitization patterns can expand over time. Testing an infant for a long list of pollens that the child has barely encountered may add little. In an older child with persistent rhinitis and wheeze, focused testing can guide environmental measures and immunotherapy decisions.

A clinician may choose skin-prick testing instead of blood testing because skin testing provides immediate results and can cover a customized set. Blood testing is useful when severe eczema limits test sites, antihistamines cannot be stopped, dermatographism makes skin responses hard to read, or access to skilled skin testing is limited. Blood testing also avoids the small risk of a systemic skin-test reaction, though venipuncture has its own practical burden.

Reading Specific IgE Results

Interpret each allergen separately. A report is not simply “positive” or “negative”; it is a map that must be matched to symptoms and exposure.

A sound interpretation asks three questions:

1. Is specific IgE clearly detectable on this assay?
2. Is the person exposed to the allergen in a meaningful setting and season?
3. Do symptoms reproducibly worsen with that exposure and improve when it is absent or treated?

When all three align, clinical allergy is more likely. When only the laboratory result is positive, the finding is sensitization of uncertain relevance.

Higher specific IgE concentrations generally increase the probability that sensitization is clinically relevant, but there is no universal inhalant cutoff that proves symptoms. The relationship differs by allergen, age, total IgE, eczema, and population. A cat result of 2 kUA/L may be important in one person and silent in another. The number cannot predict the exact symptom intensity during the next exposure.

Laboratories may show a class table similar to this:

Approximate result	Typical label	Clinical interpretation
Below assay detection or below 0.10 kUA/L	Undetectable	Systemic sensitization not demonstrated; allergy can still be missed
0.10–0.34 kUA/L	Very low or detectable	May be relevant with a strong history; often uncertain
0.35 kUA/L and above	Positive by a common convention	Probability of relevance rises with level and history, but allergy is not proved

Use the laboratory’s range rather than treating this table as a universal standard. Modern assays may quantify below 0.35 kUA/L, and some clinicians interpret those low values rather than calling them negative.

Total IgE provides context but does not identify triggers. When total IgE is extremely high, many low specific-IgE values may appear because of broad atopy or nonspecific assay effects. A ratio of specific to total IgE has research and selected clinical uses, but it is not a routine rule for every respiratory panel.

Trends are usually less important than symptom control. Specific IgE can rise or fall over years without matching day-to-day disease. Repeat testing is reasonable when exposures change, the original panel was incomplete, immunotherapy is being reconsidered, or the clinical picture changes. Repeating a stable panel every few months rarely guides care.

Rhinitis, Conjunctivitis, and Sinus Symptoms

Allergic rhinitis causes sneezing, nasal itching, clear drainage, and congestion after exposure to a relevant allergen. It often occurs with itchy, watery, red eyes. A respiratory panel can confirm systemic sensitization when the symptom pattern suggests allergy.

Timing helps separate triggers. Tree pollen often produces spring symptoms, grasses later in spring or summer, and weeds in late summer or autumn. Dust mites and animals can cause perennial symptoms. Mold exposure may be seasonal outdoors or persistent in a damp building.

Not every stuffy nose is allergic. Viral infections, medication overuse, hormonal changes, structural blockage, smoke, strong odors, and nonallergic rhinitis can look similar. Nonallergic rhinitis often features congestion and drainage without prominent itching or a matching IgE result. Some people have mixed rhinitis with both allergic and nonallergic triggers.

Skin-prick testing is often considered the preferred confirmatory test for allergic rhinitis, but serum specific IgE is a reasonable alternative. Discordant results occur. A person may have a positive skin test and negative blood test because of assay sensitivity, or the reverse because skin reactivity and serum antibody levels are not identical.

A smaller group has local allergic rhinitis. These patients have allergy-like nasal symptoms after a specific exposure but negative standard skin and blood tests. Local nasal IgE or a nasal allergen challenge may demonstrate the response in specialist settings. A negative panel therefore does not prove that every recurring seasonal symptom is nonallergic.

“Sinus” pressure can accompany nasal inflammation, but chronic rhinosinusitis is a separate diagnosis based on prolonged symptoms and objective findings from examination or imaging. Allergy may worsen it, yet a positive panel does not establish that allergen avoidance will cure polyps, infection, or structural disease.

Treatment follows symptoms and exposure, not the number alone. Intranasal corticosteroids are a mainstay for persistent allergic rhinitis. Second-generation antihistamines help sneezing and itching, and antihistamine nasal sprays can act quickly. Saline irrigation may reduce mucus and allergen load when prepared safely. Eye drops, decongestants used for limited periods, or specialist therapies may be added according to need.

Asthma and Lower-Airway Symptoms

Specific IgE can show that asthma is allergen-associated, but it cannot diagnose asthma. Asthma requires a compatible pattern—variable wheeze, breathlessness, chest tightness, or cough—and objective evidence of variable expiratory airflow when possible.

Spirometry before and after a bronchodilator is a common starting test. Peak-flow variation, bronchial challenge, or response to anti-inflammatory treatment may be used when spirometry is normal or unavailable. Blood eosinophils and fractional exhaled nitric oxide can help characterize type 2 airway inflammation, but neither replaces lung-function confirmation.

A respiratory panel is useful when symptoms worsen around a pet, during pollen season, in a damp workplace, or in a mite-rich environment. Matching can support targeted prevention and may influence candidacy for allergen immunotherapy or biologic therapy. The panel also helps distinguish allergic sensitization from nonallergic asthma triggers such as viral infections, exercise, smoke, weather changes, or irritant fumes.

Allergic rhinitis and asthma commonly coexist. Poor nasal control can worsen sleep, cough, and perceived breathing difficulty. Treating rhinitis improves upper-airway symptoms and may support overall asthma management, but patients still need an asthma-specific treatment plan.

The IgE value does not grade asthma severity. Severe asthma is defined by the treatment needed to control it and whether it remains uncontrolled despite optimized therapy. A person with low cat-specific IgE can have dangerous cat-triggered attacks, while another with a high value may have only nasal symptoms. Current asthma control, prior emergency visits, lung function, medication adherence, inhaler technique, and comorbidities carry more immediate risk information.

Do not deliberately expose someone to an inhalant allergen to “confirm” a blood result. Home pet trials, dusty-room exposure, or uncontrolled workplace rechallenge can provoke asthma. When diagnosis is uncertain, specialists can use controlled testing and exposure histories more safely.

Urgent care is needed for severe breathlessness, difficulty speaking, blue or gray lips, drowsiness, a silent chest, or poor response to rescue medication. A respiratory panel has no role in deciding whether an acute asthma attack requires treatment.

False Positives, Cross-Reactivity, and Gaps

A panel can look more extensive than the person’s true clinical allergy. Cross-reactive proteins are a major reason.

Many related grasses share similar allergens, so several grass results may be positive from one primary sensitization. Birch, alder, and hazel pollens share PR-10 proteins. Profilin and polcalcin occur across many plants and can create broad low-level pollen positivity. Cross-reactive carbohydrate determinants can bind IgE in the laboratory while causing little or no clinical respiratory disease.

Mite, cockroach, and shellfish tropomyosins can also cross-react. A positive cockroach or mite result does not diagnose shellfish allergy, and a shellfish result should not be inferred from an inhalant panel. Component-resolved testing can sometimes distinguish a genuine species-specific response from a cross-reactive pattern.

Examples of useful inhalant components include major cat and dog proteins, mite group 1 and group 2 allergens, grass marker components, birch Bet v 1, and mold Alt a 1. Molecular testing is most helpful when extract results conflict with exposure, when many pollens are positive, or when immunotherapy selection depends on identifying genuine sensitization. It is not required for every patient.

False-negative or incomplete evaluations occur when:

• the relevant local allergen is absent from the panel;
• the extract lacks a clinically important protein;
• specific IgE is below assay detection;
• symptoms are caused by non-IgE inflammation or irritants;
• local allergic rhinitis is present;
• the wrong season or exposure was assumed;
• the patient has a rare occupational allergen.

Antihistamines generally do not suppress serum specific IgE and usually can be continued for blood testing. Systemic corticosteroids and inhaled corticosteroids also do not simply erase sensitization, although long-term immune-modifying therapies can alter disease and some laboratory values over time. The ordering laboratory or clinician should advise on unusual biologic therapies or immunosuppression.

A positive mold result deserves careful wording. It confirms sensitization to the tested mold extract, not “toxic mold illness,” building contamination, or a need for expensive whole-house remediation. Visible moisture damage should be repaired for general health, but environmental sampling and medical IgE testing answer different questions.

Pet results also require nuance. Cat and dog allergens remain airborne, adhere to clothing, and persist after an animal leaves. Symptoms may improve slowly after exposure reduction. A positive result does not automatically require rehoming; decisions should consider symptom severity, asthma risk, realistic control measures, and treatment options.

Turning Results Into a Treatment Plan

A useful report produces a prioritized trigger list rather than a long avoidance list. Start with allergens that have the strongest match between IgE, exposure, and symptoms.

For pollens, practical measures include tracking local counts, keeping windows closed during peak periods when feasible, changing clothes after heavy outdoor exposure, showering before bed, and using effective medication before the expected season. Masks can reduce exposure during mowing or high-pollen work. Complete outdoor avoidance is rarely realistic or necessary.

For dust mites, the most helpful combined approach may include humidity control, hot washing of bedding when fabric allows, allergen-impermeable mattress and pillow covers, and reducing reservoirs in the bedroom. A single intervention often has a modest effect. Do not use chemical acaricides or major home renovations without a clear reason.

For animals, keep the pet out of the bedroom, use high-efficiency filtration where appropriate, clean fabrics, and reduce close face contact. Bathing an animal provides only temporary allergen reduction. If asthma is severe and clearly pet-triggered, more substantial exposure changes may be needed.

For cockroach or rodent sensitization, integrated pest management is more effective than repeated spraying alone. It combines sealing entry points, controlling food and water sources, traps or baits, cleaning reservoirs, and professional help when needed. Occupational triggers may require ventilation, protective equipment, process changes, or workplace health involvement.

Allergen immunotherapy may be considered when allergic rhinitis with or without allergic asthma remains troublesome despite appropriate medication and exposure measures, or when a person wants a disease-modifying option. The chosen allergen must be clinically relevant. Immunotherapy is not based on every positive panel item, and uncontrolled asthma raises treatment risk.

Before an allergy visit, prepare a one-page summary with:

• symptoms and months of the year;
• home, animal, and workplace exposures;
• current nasal and asthma medicines;
• prior skin or blood tests;
• asthma attacks, emergency care, and lung results;
• which avoidance steps helped or failed.

Questions to ask include:

• Which positives clearly match my symptoms?
• Are any results likely cross-reactive?
• Did the panel omit important local or occupational allergens?
• Would skin testing or component testing change the plan?
• Do I need spirometry or additional asthma assessment?
• Am I a candidate for allergen immunotherapy?
• Which environmental changes are worth the effort?

Avoid ordering repeated broad panels to monitor whether avoidance “worked.” Symptom scores, medication use, sleep, activity, asthma control, and objective lung function are better measures of improvement. Specific IgE can remain positive for years even when clinical control is excellent.

References

• Allergic rhinitis 2024 (Review)
• EAACI Molecular Allergology User’s Guide 2.0 2023 (Guideline)
• Clinical Practice Guideline: Immunotherapy for Inhalant Allergy 2024 (Guideline)
• Molecular allergology: a clinical laboratory tool for precision diagnosis and personalized management of allergic diseases 2024 (Review)
• Update on Asthma Management Guidelines 2024 (Review)
• Summary Guide for Asthma Management and Prevention 2025 (Guideline)

Disclaimer

This article provides general information and cannot diagnose allergic rhinitis, asthma, occupational allergy, or any specific trigger. Results should be interpreted with symptoms, exposure history, and appropriate clinical testing. Severe or rapidly worsening breathing symptoms require urgent medical care.